Pharmaceutical

AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.  

Oct 24, 2024 - 04:00
AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD
This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.  
Read the original article

Tags:

Previous Article

FDA approves Alvotech and Teva’s SELARSDI for new indications

Next Article

Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator gains $100m in Series A funding for antibody ...

Aug 29, 2024

Can routinely collected primary care data drive life sciences investment in the UK?

Can routinely collected primary care data drive life sc...

Jun 30, 2024

STAT+: Once a Silicon Valley darling, Mindstrong sells its mental health technology for parts

STAT+: Once a Silicon Valley darling, Mindstrong sells ...

Mar 22, 2023